|Bid||0.00 x 1200|
|Ask||0.00 x 1400|
|Day's Range||122.69 - 124.91|
|52 Week Range||102.10 - 144.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||158.00|
Alexion Pharmaceuticals today announced that management will present at Morgan Stanley’s 16th Annual Global Healthcare Conference in New York, NY on Friday, September 14, 2018 at 11:05 a.m., EDT.
In September 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given Alexion stock a “buy” or higher rating, and two analysts have given Alexion a “hold” rating. The mean rating for Alexion stock is $1.83 with a target price of $158.41, implying an upside potential of 32.9% over Alexion’s closing price of $119.20 on September 4.
Alexion Pharmaceuticals’ (ALXN) Kanuma is the only enzyme replacement therapy approved for treating lysosomal acid lipase deficiency, which is an ultra-rare disease associated with premature mortality and significant morbidity. Alexion’s Kanuma generated total sales of $21.4 million in the second quarter as compared with $15.3 million in the second quarter of 2017. Its sales in Europe and the Asia Pacific increased from $3.3 million and $600,000 in the second quarter of 2017 to $5.8 million and $1.1 million in the second quarter 2018.
This increase was attributable to higher professional services, asset-related charges, and charitable contributions. During the second quarter, Alexion incurred $803.7 million in acquired in-process research and development expenses related to its acquisition of Wilson Therapeutics. While Alexion had generated an operating income of $226.7 million in the second quarter of 2017, in the second quarter of 2018, it incurred an operating loss of $400.1 million.
Alexion Pharmaceuticals’ (ALXN) products on the market include Soliris, Strensiq, and Kanuma. Alexion’s Soliris, a humanized monoclonal antibody, is targeted for treating inflammation associated with chronic disorders in hematology, nephrology, and neurology.
Alexion Pharmaceuticals (ALXN), a global biopharmaceutical company, is focused on developing and commercializing therapies for rare diseases. Its research efforts are focused on the therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. It has two innovative enzyme replacement therapies for hypophosphatasia and lysosomal acid lipase deficiency, two ultra-rare metabolic disorders.
MARKET PULSE TV ratings company Nielsen Holdings Plc (nlsn) said Wednesday it has appointed David Anderson as chief financial officer effective Sept. 10. Anderson, who has worked at a number of public companies, including serving as CFO of aerospace and defense company Honeywell international Inc.
In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017, reflecting a ~17% YoY (year-over-year) growth. It reported net revenues of $746.3 million in the first half of 2018 compared to $621.2 million in the first half of 2017, reflecting a ~2% YoY growth.
On August 30, BioMarin Pharmaceutical (BMRN) stock closed at $99.26, which is ~7% below its 52-week high of $106.20 on August 2. It hit its 52-week low of $75.81 on April 6.
Alexion Pharmaceuticals today announced that management will present at Citi’s 13th Annual Biotech Conference in Boston, MA on Thursday, September 6, 2018 at 8:15 a.m., EDT.
Today, the European Commission (or EC) approved the marketing authorization of Jazz Pharmaceuticals’ (JAZZ) Vyxeos. This authorization covers the treatment of adult individuals with newly diagnosed treatment-associated acute myeloid leukemia with myelodysplasia-related changes (or AML-MRC).
The biotech sector witnesses a pretty low key week with a handful of regulatory updates. Regeneron secures an FDA approval for the label expansion of its key drug Eylea.
The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Nike and Alexion Pharmaceuticals staked out early leads Monday, as strength across global markets helped boost stocks in opening trade.
Alexion Pharmaceuticals, Inc. (ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s Biologics License Application (BLA) for approval of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). The Phase 3 clinical development program of ALXN1210 is the largest-ever Phase 3 program in PNH.
Alnylam Pharmaceuticals’ (ALNY) investigational RNAi therapeutic drug lumasiran is being developed for the treatment of primary hyperoxaluria type 1 (or PH1). Alnylam expects to initiate a Phase 3 trial of the drug in 2018, with its results expected in late 2019.
In August 2018, Jazz Pharmaceuticals (JAZZ) and the University of Texas MD Anderson Cancer Center entered a five-year collaboration agreement to investigate therapies for the treatment of multiple hematologic malignancies such as AML (acute myeloid leukemia) and myelodysplastic syndrome.
On August 7, Jazz Pharmaceuticals (JAZZ) released its second-quarter 2018 financial results. Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.
NEW YORK, Aug. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Washington ...
Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.